3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Motor Activity
12
Breast Neoplasms
9
Polycystic Ovary Syndrome
8
Obesity
7
Colorectal Neoplasms
7
Weight Loss
5
Colonic Neoplasms
5
Neoplasms
4
Endometrial Neoplasms
4
Prostatic Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Recurrence
2
Pancreatic Neoplasms
2
Overweight
2
Ovarian Neoplasms
2
Malnutrition
2
Lymphoma, Follicular
2
Lymphoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunction, Physiological
1
Sarcopenia
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyps
1
Patient Compliance
1
Interventions
Cyclophosphamide
151
Dexamethasone
140
Rituximab
83
fludarabine
78
Cytarabine
69
Lenalidomide
68
Bortezomib
63
fludarabine phosphate
62
Gemcitabine
62
venetoclax
54
Etoposide
53
pembrolizumab
52
pomalidomide
48
Paclitaxel
48
Cisplatin
47
Carboplatin
47
Peripheral Blood Stem Cell Transplantation
46
Filgrastim
40
Radiotherapy
39
Calcium Dobesilate
36
Busulfan
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
29
Vincristine
28
Temozolomide
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Recurrence
×
Diet
×
Clear all
NCT07494201
2026-03-27
MIMICC
Fondazione del Piemonte per l'Oncologia
Phase NA
Recruiting
2,500 enrolled
NCT02035631
2014-01-14
PREDICOP
Institut Català d'Oncologia
Phase 3
Unknown
2,000 enrolled